Glaucoma is the leading cause of blindness and is often related to high intraocular pressure.  However, over 10% have progressive visual loss despite optimal intraocular pressure lowering. Our drugs are proven to reduce visual loss in animal studies.  Non-human primate studies are pending, and human trials will begin in 2025.

Diabetic Retinopathy (DR) is caused by damage to blood vessels in the retina of diabetic patients leading to vision loss. Our DR therapeutics are in the early stages of pre-clinical studies

Eyegenex

Org chart

Teams

Offices